
Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target
Ligand Pharmaceuticals (LGND) Analyst Ratings
Bulls say
Ligand Pharmaceuticals is a promising investment option due to its unique business model and strategic partnerships with pharmaceutical companies. With a strong focus on sustainability and responsible business practices, the company has a diverse portfolio of assets and continues to make acquisitions to drive growth and profitability. Despite potential risks, Ligand's recent investments and raised stock price target indicate a positive outlook for the company's future performance.
Bears say
Ligand Pharmaceuticals is heavily reliant on royalty revenue, which poses a risk if sales of the company's partnered products slow down or decline. The company's business model is also heavily dependent on acquisitions and partnerships, which may not pan out as expected and could negatively impact the company's operations. Additionally, the company faces risks related to its drugs in development, such as clinical trial disappointments or failure to receive approvals. Despite its efforts towards sustainability and diversification, there is still a potential for setbacks and challenges in the company's operations.
This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Ligand Pharmaceuticals (LGND) Analyst Forecast & Price Prediction
Start investing in Ligand Pharmaceuticals (LGND)
Order type
Buy in
Order amount
Est. shares
0 shares